Heterocyclic-substituted pyrimidopyran compound and use thereof

Piperazine-bridged ring-substituted pyrimidinepyran compounds serve as potent and selective GPR119 receptor agonists, addressing the limitations of existing pharmaceuticals in treating metabolic disorders by enhancing metabolic activity.

HK40135136APending Publication Date: 2026-07-17D3 BIO (WUXI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
D3 BIO (WUXI) CO LTD
Filing Date
2026-05-11
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Current pharmaceutical compounds targeting GPR119 receptor agonism are limited in efficacy and specificity, particularly in addressing metabolic disorders such as diabetes and obesity, necessitating the development of more potent and selective agents.

Method used

Development of piperazine-bridged ring-substituted pyrimidinepyran compounds and their pharmaceutically acceptable salts, which act as potent GPR119 receptor agonists, enhancing metabolic activity and providing therapeutic benefits.

Benefits of technology

The piperazine-bridged ring-substituted pyrimidinepyran compounds demonstrate improved efficacy and selectivity as GPR119 receptor agonists, offering potential therapeutic benefits for metabolic disorders like diabetes and obesity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a piperazine bridged ring substituted pyrimidinopyran compound and application thereof, and particularly discloses a compound as shown in formula (I ''), (I ') or formula (I), and a stereoisomer and pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480019726.1 (22) Application Date 2024.03.22 (66) Domestic Priority Data 202310290481.3 2023.03.23 CN 202311634664.9 2023.11.30 CN 202410309827.4 2024.03.18 CN (85) PCT International Application Entering National Phase Date 2025.09.17 (86) PCT International Application Application Data PCT / CN2024 / 083328 2024.03.22 (87) PCT International Application Publication Data WO2024 / 193698 ZH 2024.09.26 (71) Applicant: Deshengji Pharmaceutical (Wuxi) Co., Ltd. Address: Room 324, No. 88, Meiliang Road, Mashan Street, Binhu District, Wuxi City, Jiangsu Province, 214092, China (72) Inventors: Chen Shuhui, Chen Zhijian, Robert Mook Jr., Wu Wentao, Yang Ping, Zhang Jing, Zhang Yang, Zhu Jiuxiang (74) Patent Agency: Beijing Liushen Law Firm, 11105 Patent Attorney: Mou Ke (51) Int.Cl. C07D 519 / 00 (2006.01) C07D 403 / 14 (2006.01) C07D 403 / 04 (2006.01) C07D 491 / 052 (2006.01) A61K 31 / 517 (2006.01) A61K 31 / 519 (2006.01) A61P 35 / 00 (2006.01) A61P 35 / 02(2006.01) (54) Invention Title: Heterocyclic Substituted Pyrimidinepyran Compounds and Their Applications (57) Abstract: This invention discloses a class of piperazine-bridged ring-substituted pyrimidinepyran compounds and their applications, specifically disclosing compounds of formula (I″), (I′) or formula (I), their stereoisomers, and pharmaceutically acceptable salts thereof. CN 120936608 A 2025.11.11 CN 1 20 93 66 08 A